clinical_trial

Mondego Bio Starts First-in-Human Trial of Oral PTPN2/PTPN1 Inhibitor

Image
Mondego Bio Starts First-in-Human Trial of Oral PTPN2/PTPN1 Inhibitor

Cantanhede – November 05, 2026 -- Mondego Bio has started a first-in-human Phase 1 study of MB-388, an oral dual PTPN2/PTPN1 inhibitor built to overcome resistance to cancer immunotherapy, with initial human pharmacokinetic and pharmacodynamic data due in December 2026.

Phase 1a tests dose escalation in healthy volunteers

The randomized, double-blind, placebo-controlled study will evaluate single and multiple ascending doses of MB-388. It will assess safety and tolerability, characterize pharmacokinetics and measure target engagement using blood-based pharmacodynamic biomarkers.

CEO Nikolay Savchuk said the study will define the relationship between exposure, pathway engagement and tolerability ahead of the planned patient study.

Cognixion Enrolls 30 ALS Patients in NIH-Funded BCI Trial

Image
Cognixion Enrolls 30 ALS Patients in NIH-Funded BCI Trial

Santa Barbara – November 04, 2026 -- Cognixion Corporation is enrolling 30 US adults with amyotrophic lateral sclerosis (ALS) in the CHOICE study, which tests its wearable brain-computer interface (BCI) against the eye-tracking speech devices patients use today. The trial is registered on ClinicalTrials.gov as NCT07871071 and is funded entirely by federal money from the National Institute on Deafness and Other Communication Disorders (NIDCD), part of the National Institutes of Health.

Participants test three communication options at home over 12 weeks

Each participant uses their own eye-tracking speech generating tablet, a head-worn Cognixion BCI with augmented reality display glasses, and a touchscreen-based version of the Cognixion system. Participants choose which option to use in each session. The time they voluntarily spend with each is the study's primary outcome measure.

Baystate Health First in U.S. to Enroll Patients in PIONEER Aneurysm Trial

Image
Baystate Health First in U.S. to Enroll Patients in PIONEER Aneurysm Trial

Springfield, Mass. – September 26, 2026 -- Baystate Health has become the first hospital in the United States to enroll patients in the PIONEER trial, a national study evaluating Balt Corporation's Silk Vista Baby flow-diverting stent for unruptured brain aneurysms in small blood vessels, treating its first three patients within days of receiving approval.

Baystate enrolls first three U.S. patients in national aneurysm device trial

The PIONEER study is a prospective, multicenter, single-arm trial spanning 35 leading centers in the United States and 5 in Canada, designed to assess the safety and efficacy of the Silk Vista Baby device. Balt Corporation launched the trial to satisfy FDA requirements for broader U.S. market access after the device received full approval from the Centers for Medicare & Medicaid Services following a prolonged review process.

Nanochon Treats First Patient in Chondrograft Knee Cartilage Trial

Image
Nanochon Treats First Patient in Chondrograft Knee Cartilage Trial

Baltimore – September 08, 2026 -- Nanochon, Inc. has completed the first procedure in its First-in-Human clinical study for ChondrograftTM, a 3D-printed implant targeting articular cartilage defects of the knee, with the surgery performed at The Panama Clinic in Panama City.

Drs. Osorio and Tufiño perform first Chondrograft implant procedure in Panama

Dr. Juan Osorio, the study's Principal Investigator, and Dr. Emilio Tufiño, both specialists in regenerative sports medicine, carried out the bone-sparing, minimally invasive procedure. Dr. Tufiño noted the dedicated instrumentation set made the operation simple and efficient.

TCAI Becomes First US Site to Trial New Pulsed Field Ablation System

Austin, Texas – September 08, 2026 -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has become the first center in the United States to enroll a patient in a clinical trial evaluating a next-generation pulsed field ablation mapping and ablation system for paroxysmal and persistent atrial fibrillation.

TCAI performs first US procedure under global trial protocol

Andrea Natale, M.D., executive medical director of TCAI and global principal investigator for the trial, performed the inaugural procedure. The study is designed to assess the safety and efficacy of the catheter-based system in patients with paroxysmal atrial fibrillation, defined as symptomatic episodes lasting seven days or less, and persistent atrial fibrillation, sustained arrhythmia lasting longer than one week.